DJNJ2 Stock Overview
Researches, develops, manufactures, and sells various products in the healthcare field worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Johnson & Johnson Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$815.00 |
52 Week High | US$898.00 |
52 Week Low | US$394.50 |
Beta | 0.53 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 241.00% |
Recent News & Updates
Recent updates
Shareholder Returns
DJNJ2 | AR Pharmaceuticals | AR Market | |
---|---|---|---|
7D | 0% | -1.1% | 0.5% |
1Y | n/a | -27.1% | 270.6% |
Return vs Industry: Insufficient data to determine how DJNJ2 performed against the AR Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DJNJ2 performed against the AR Market.
Price Volatility
DJNJ2 volatility | |
---|---|
DJNJ2 Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 4.7% |
Market Average Movement | 7.3% |
10% most volatile stocks in AR Market | 9.6% |
10% least volatile stocks in AR Market | 5.4% |
Stable Share Price: DJNJ2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DJNJ2's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1886 | 152,700 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Johnson & Johnson Fundamentals Summary
DJNJ2 fundamental statistics | |
---|---|
Market cap | AR$321.27t |
Earnings (TTM) | AR$11.49t |
Revenue (TTM) | AR$81.04t |
28.0x
P/E Ratio4.0x
P/S RatioIs DJNJ2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DJNJ2 income statement (TTM) | |
---|---|
Revenue | US$98.66b |
Cost of Revenue | US$32.01b |
Gross Profit | US$66.65b |
Other Expenses | US$52.66b |
Earnings | US$13.99b |
Last Reported Earnings
Oct 01, 2023
Next Earnings Date
Jan 23, 2024
Earnings per share (EPS) | 5.81 |
Gross Margin | 67.56% |
Net Profit Margin | 14.18% |
Debt/Equity Ratio | 42.0% |
How did DJNJ2 perform over the long term?
See historical performance and comparison